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ABSTRACT
Depression and anxiety are highly prevalent in elderly COPD patients. Since symptoms of
depression and anxiety reduce quality of life in these patients, treatments aimed at improving
mental health may improve their quality of life. This study evaluated the effectiveness of a
nurse-led Minimal Psychological Intervention (MPI) in reducing depression and anxiety, and
improving disease-specific quality of life in elderly COPD patients. In a randomized controlled
trial an MPI was compared with usual care in COPD patients. COPD patients aged 60 years or
over, and with minor or mild to moderate major depression were recruited in primary care (n
= 187). The intervention was based on principles of cognitive behavioural therapy (CBT) and
self-management. Outcomes were symptoms of depression, symptoms of anxiety, and disease-
specific quality of life, assessed at baseline and at one week and three and nine months after the
intervention. Results showed that patients receiving the MPI had significantly fewer depressive
symptoms (mean BDI difference 2.92, p = 0.04) and fewer symptoms of anxiety (mean SCL
difference 3.69, p = 0.003) at nine months than patients receiving usual care. Further, mean
SGRQ scores were significantly more favourable in the intervention group than in the control
group after nine months (mean SGRQ difference 7.94, p = 0.004). To conclude, our nurse-led
MPI reduced symptoms of depression and anxiety and improved disease-specific quality of
life in elderly COPD patients. The MPI appears to be a valuable addition to existing disease-
management programmes for COPD patients.
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Chronic obstructive pulmonary disease (COPD) is a preva-
lent disease in elderly persons (1). Since COPD is irreversible,
disabling and progressive, treatment aims to prevent deteriora-
tion of the disease and maintain a high quality of life.
Depression and anxiety are highly prevalent in elderly COPD
patients (2, 3), and both are known to reduce quality of life
(4–6). Recent research has shown that depressive symptoms are
strongly associated with worse quality of life, even after severity
of COPD was taken into account (7). The exact causal mech-
anisms for depression in COPD are not well known, making
it hard to select therapeutic targets. However, since COPD is
characterized by systemic inflammation (8), and depression is
known to have an adverse influence on immunologic processes

























































(9, 10), co-occurrence of COPD and depression may lead to
further deterioration of patients’ health status due to interac-
tion. Breaking through this downward spiral may thus be an
important step towards improving quality of life. In view of the
relationship between quality of life and depression and anxiety,
treatments to reduce depression and anxiety in COPD patients
may also improve their quality of life (3, 11).
Depression and anxiety can be treated with antidepressants
(3, 12, 13), although some claim that the evidence for their ef-
fectiveness in older COPD patients is sparse and inconclusive
(12, 14). Furthermore, treatment with antidepressants may be
complicated by problems like medication side effects or refusal
of treatment by COPD patients (12, 14). Psychological and self-
management interventions may be better alternatives, especially
as they teach patients valuable and enduring skills to cope with
their disease, thus potentially ensuring a more lasting effect,
extending beyond the end of treatment. Furthermore, these in-
terventions can be administered by trained paramedical profes-
sionals, like nurses, complementing the care of physicians (15,
16). Few trials have assessed the effectiveness of psychological
and self-management interventions in elderly COPD patients in
terms of reducing symptoms of depression and anxiety. A re-
cent systematic review based on four, relatively small, studies,
found only limited evidence for the effectiveness of cognitive
behavioural therapy (CBT) in reducing anxiety and depression
in COPD patients, although the direction of treatment effects
on both depression and anxiety scales mainly favoured CBT.
(17) The largest trial to date on CBT on COPD is a study by
Kunik and colleagues (18). This study showed that CBT as
well as COPD education improved quality of life, depression
and anxiety symptoms, among persons with high scores on in-
ventories for anxiety and depression symptomatology. A recent
review of self-management education for COPD patients pro-
duced inconclusive results for the effect on the generic quality of
life outcome, but found significant effects on a disease-specific
quality of life measure (19). Both reviews recommend further
research into CBT and self-management for COPD patients.
We have developed a nurse-administered minimal psycho-
logical intervention (MPI) based on the principles of CBT and
self-management. The intervention has previously been evalu-
ated in the Depression in Elderly with long-Term Afflictions
(DELTA) study in a population of elderly patients with diabetes
or COPD (20). The current contribution reports on the effect
of the MPI on disease-specific quality of life and symptoms
of depression and anxiety in the subgroup of elderly COPD pa-
tients with co-morbid depression. We hypothesized that our MPI
would reduce symptoms of depression and anxiety and would
also improve disease-specific quality of life.
MATERIALS & METHODS
Study design
Detailed information on the study protocol has been pub-
lished elsewhere (20, 21). Briefly, a randomized controlled trial
was conducted, with patients allocated to either the MPI or
care as usual after signing informed consent. Self-administered
questionnaires were used to collect data at baseline and at one
week and three and nine months after the treatment period. Data
entry was performed by researchers blinded for the allocation.
Approval for this study was obtained from the Medical Ethics
Committee of Maastricht University / University Hospital Maas-
tricht.
Participants and procedures
Between October 2003 and May 2005, patients were re-
cruited in 89 general practices in the south of the Dutch province
of Limburg. We first selected all patients aged 60 years and older
with an International Classification of Primary Care (ICPC) code
for emphysema / COPD or chronic bronchitis. If ICPC codes
were not available, lists of patients with repeat prescriptions
for bronchodilatory drugs were obtained. The patients’ general
practitioners (GPs) then excluded from this initial broad selec-
tion all patients who did not have COPD, were bedridden, were
on a waiting list for a nursing home, had major depression, used
antidepressants, had major psychiatric conditions or were cur-
rently receiving psychosocial/psychiatric treatment, had serious
cognitive problems, had recently lost their spouse or were not
fluent in Dutch. All remaining patients aged 60 years and older
who did have COPD according to their GP were sent a depres-
sion screening questionnaire (Patient Health Questionnaire-9 –
PHQ-9) (22). After the PHQ-9 screening, all patients who re-
ported having at least two symptoms of depression, one being
loss of interest or depressed mood, were invited to a diagnos-
tic interview, consisting of the Mini International Neuropsychi-
atric Interview (MINI) (23) and the Hamilton Depression Rating
Scale (HDRS) (24). The interview was conducted at the patients’
home by a trained nurse. Patients with minor depression, mild
major depression, moderate major depression or dysthymia were
included in the study. Patients with severe major depression ac-
cording to the HDRS (HDRS > 18) and patients with suicidal
risk were excluded and referred back to their GP. All COPD pa-
tients thus included (n = 187) signed an informed consent form
and were randomized. The researchers entered patients into a
computer connected to an external agency, which performed the
randomization using a computerized random number generator.
A block randomization scheme was used, stratified for general
practice. Block size was set at 2, as we expected to include only
a small number of patients per practice.
Intervention and usual care
Patients allocated to the intervention group received the MPI
at home, supplementary to usual care according to the clini-
cal Guidelines for the Treatment of COPD of the Dutch Col-
lege of General Practitioners (25). The intervention is a nurse-
administered, minimal psychological intervention, consisting of
elements of CBT and self-management. Nurses were trained by
a GP, a psychologist and a psychiatrist, and had regular booster
sessions with the psychiatrist. The intervention was tailored
to individual patients. Depending upon progress, patients re-
ceived two to ten visits over a period of at most three months.

























































Table 1. Phases of the Minimal Psychological Intervention (MPI)
Phase Description
1 The nurse explores the patient’s feelings, cognitions and behaviours
2 The patient keeps a diary, where he or she records symptoms, complaints, thoughts, worries, related feelings and
behaviour
3 The patient is challenged to link his or her mood to the consequent behaviour, using information from the diary
4 The self-management approach is introduced. The patient explores possibilities to alter his or her behaviour and draws
up an action plan
5 Evaluation of progress in achieving the goals of the action plan
Patients had on average four intervention contacts, each lasting
approximately one hour. Table 1 lists the five phases of the in-
tervention; a more detailed description of the intervention has
been published elsewhere (21, 26). To ensure that the nurses
adhered to the protocol during the study, they were asked to
keep checklists, covering all essential intervention steps, for
each patient. Examination of these lists showed that nurses had
adhered closely to the guidelines in the protocol (27). Patients
allocated to the control group received care as usual according
to the above-mentioned clinical guidelines.
Outcome measures
Data were collected by means of self-administered question-
naires. Depressive symptoms were assessed using the Beck De-
pression Inventory (BDI) (28) and anxiety was assessed using
the anxiety subscale of the Symptom Checklist-90 (SCL) (29).
Demographic information was collected at the time of the PHQ-
9 screening. Disease-specific quality of life was assessed using
the Saint George’s Respiratory Questionnaire (SGRQ) (30). The
SGRQ consists of a total score that summarizes the overall im-
pact of COPD on health status, and three subscales: the activity
scale (activities that cause or are limited by breathlessness),
the impact scale (social functioning and psychological distur-
bances) and the symptom scale (effects, frequency and severity
of respiratory symptoms). Missing item scores on the SGRQ
and SCL were imputed according to the recommendations in
their respective manuals; missing items on the BDI were im-
puted with the patient’s mean item score as long as at least 50%
of the items had been completed.
Statistical analysis
The power calculation for the DELTA study was based on
the BDI in the total group of diabetes and COPD patients (20).
According to this calculation, assuming an α of 0.05 and a
1 – β (power) of 0.90, we needed to include 2 × 96 = 192
patients (48 COPD and 48 DM patients in the intervention group
and 48 COPD and 48 DM patients in the control group) to
allow us to detect a minimum clinically relevant difference of
18% in improvement (≥50% reduction of BDI score relative to
baseline). (31) Anticipating an attrition rate of approximately
30% and the potential need for subgroup analyses, we decided
to recruit a gross number of 360 patients. In the group of COPD
patients included in the current study (n = 187), a difference of
7.83 on the SGRQ total score would be significant at the 5%
level. A difference of four points on the SGRQ is considered
clinically relevant.
Analyses were based on the intention-to-treat principle. The
comparability of groups was checked by means of t-tests and
Chi-square tests for demographic and outcome variables. Mixed
model, repeated-measure ANCOVA analysis was used to test the
differences between groups at follow-up measurements. Advan-
tages of mixed model analysis include that it can handle miss-
ing observations, and error terms are estimated more precisely,
thereby further increasing power. Fixed effects included in the
model were: age, gender, educational level, treatment group,
baseline value of outcome, time and the product term of time
and group. Several random effects and covariance matrices were
tested, using -2 log likelihood tests to decide which model had
the best fit. Maximum Likelihood models were then run, whose
results are presented here.
In addition, effect sizes (d) were calculated by dividing the
difference in mean group scores by the pooled standard devia-
tion (32). The percentage of patients showing an improvement
of 4 points on the SGRQ total score was also computed and
differences between groups were tested with Chi-square tests.
Additional per-protocol analyses were done, including pa-
tients who had received a complete intervention (all core steps
of the intervention delivered, based on nurses’ checklists, n =
60 (27)) and excluding 4 control patients who had received in-
formation on the content of the intervention and had benefited
from this (based on self-report). We also performed analyses
in which missing observations were imputed (last observation
carried forward – LOCF).
RESULTS
Figure 1 shows the flow of COPD patients in the trial. Of
the 506 patients invited for a MINI, 164 did not meet the in-
clusion criteria. The 41 patients who were eligible but refused
to participate were significantly older than patients who did
enter the study. Of the 187 patients who were included, 96
were offered the MPI, and 91 received usual care. The dropout-
rate was 36%, which was slightly higher than the anticipated
30%. Although the difference was not statistically significant,
the dropout-rate was somewhat higher in the intervention group
than in the control group (40% vs. 33%, p = 0.35). Furthermore,
dropouts overall had a higher age and higher baseline BDI and
SGRQ scores (activity and impact subscales and total score),






























































Allocated to intervention (n=96)
Received allocated intervention (n=71)
Discontinued intervention (n=16)





Deceased (n=2)Other reasons (n=1)
Did not receive allocated intervention (n=9)
Lack of perceived useful (n=6)
Physical decline (n=2)
Other reasons (n=1)
Allocated to usual care (n=91)
































































Invited for MINI (n=506)
Excluded (n=319)
Not participating in MINI:
Refused to participate in MINI or could
not be reached (n=114)
Participating in MINI:
Not meeting inclusion criteria (n=164)
Refused to participate in trial (n=41)
Figure 1. Patient flow and follow up in the study.

























































Table 2. Comparability of MPI intervention and control groups regarding socio-demographic variables and baseline
values of outcomes
Usual care MPI P-value
Variable n = 91 n = 96
Age, yrs (SD) 71.5 (7.1) 70.5 (6.3) 0.32
Sex, No. (%)
Male 53 (58.2) 59 (61.5)
Female 38 (41.8) 37 (38.5) 0.65
Education level†, No. (%)
Low 31 (34.1) 36 (37.5)
Medium 24 (26.4) 31 (32.3)
High 36 (39.6) 29 (30.2) 0.39
BDI, mean (SD) 18.3 (7.2) 17.1 (6.5) 0.23
SCL, mean (SD) 20.4 (7.3) 20.6 (6.2) 0.83
SGRQ total score, mean (SD) 56.8 (19.5) 54.9 (17.5) 0.55
SGRQ activity, mean (SD) 70.9 (21.0) 70.6 (20.9) 0.79
SGRQ impact, mean (SD) 46.2 (22.3) 45.9 (20.8) 0.91
SGRQ symptoms, mean (SD) 56.7 (27.5) 60.9 (25.2) 0.30
† Low refers to primary school only, medium refers to lower vocational training or lower general education, high refers to
higher vocational training, secondary school, higher professional education and university training.
Range of the BDI is 0–63, with 0 as the most favorable outcome; range of SGRQ total scale and subscales is 0–100,
with 0 as the most favorable score; range of the SCL Anxiety scale is 1–50, with 1 as the most favorable outcome.
indicating worse depression states and lower quality of life (data
not shown).
Table 2 shows the comparability of groups at baseline. None
of the differences between the intervention and control groups
were statistically significant, although the control group was
slightly older and had a somewhat higher educational level than
the intervention group. In addition, the control group had some-
what higher mean BDI and SGRQ total scores, indicating a
higher level of depressive symptoms and lower quality of life
than the intervention group.
Results of the mixed model analyses are presented in Table
3. On average, we found significantly lower scores for both the
depression and anxiety outcomes at nine months in the interven-
tion group compared with the control group, indicating fewer
symptoms (BDI p = 0.04; SCL p = 0.003). As for disease-
specific quality of life, we found that the intervention group
had significantly better scores on the SGRQ activity subscale
than controls at one week (p = 0.004) and three months (p =
0.02) after the intervention, but the mean difference between
groups was no longer significant at nine months after the in-
tervention (p = 0.09). Results for the SGRQ impact subscale
showed the opposite pattern: there were no significant differ-
ences immediately after the intervention, but the intervention
group had significantly better scores than the control group at
three months (p = 0.02) and nine months (p = 0.003) after
the intervention. No effects were found on the SGRQ symptom
subscale, but the SGRQ total scores showed that, on average,
intervention patients had a significantly better quality of life
than controls at all follow-up measurements (1 wk p = 0.03; 3
months p = 0.005; 9 months p = 0.004). In terms of clinical
relevance, a four-point change relative to baseline on the SGRQ
total score was more often seen in intervention patients than in
control patients at all follow-up measurements, with a signif-
icant difference at nine months (52% vs. 29%, p = 0.03, not
tabulated). Effect sizes corresponding to significant results can
all be classified as medium. (32) Additional per-protocol and
LOCF analyses produced similar results (data not shown).
DISCUSSION
This study showed that a nurse-led minimal psychological in-
tervention significantly reduced depressive symptoms and pre-
vented aggravation of anxiety in elderly COPD patients with
minor to moderate depression. The intervention also improved
disease-specific quality of life. Corresponding effect sizes were
all medium (32).
Our tailor-made intervention was intended to educate pa-
tients to take responsibility for the day-to-day management of
their own illness and its consequences. This was achieved by
improving patients’ understanding of the relation between their
behaviour and consequent mood, by challenging them to draw
up action plans to change their behaviour, and by teaching them
self-management skills that they could apply in daily life. The
study results indicate that the aim of the intervention was in-
deed achieved, as differences between groups became larger
over time for all outcomes, except for the Activity subscale.
This may very well mean that patients learned skills and contin-
ued to apply them in daily life during the follow-up period, even
becoming more successful over time. Winning back control over
daily symptoms by learning coping skills seems very rewarding
especially for COPD patients, as many of them have developed
a tendency towards ‘learned helplessness’ during the course of
their disease. This explanation is further supported by the results
of analyses showing positive effects on self-efficacy, which is a
prerequisites for improvement of self-care. Also social partici-
pation appeared to be influenced positively (33). Also, improved

























































Table 3. Outcomes on quality of life, depression and anxiety
Usual Care N = 91
Mean (SE)∗ N∗∗






Depression and anxiety scales
BDI
After 1 week 17.31 (0.77) 68 15.45 (0.80) 64 1.85 (−0.36 to 4.06) 0.10 0.29
After 3 months 17.57 (0.82) 63 15.59 (0.87) 57 1.98 (−0.39 to 4.36) 0.10 0.31
After 9 months 17.96 (0.96) 59 15.04 (1.00) 58 2.92 (0.17 to 5.68) 0.04 0.39
SCL Anxiety
After 1 week 21.43 (0.69) 66 20.76 (0.73) 61 0.67 (−1.31 to 2.64) 0.51 0.11
After 3 months 21.66 (0.74) 61 20.87 (0.78) 55 0.79 (−1.34 to 2.91) 0.47 0.14
After 9 months 23.54 (0.84) 58 19.85 (0.87) 57 3.69 (1.29 to 6.09) 0.003 0.57
SGRQ subscales
Activity subscale
After 1 week 70.51 (1.75) 54 62.99 (1.92) 46 7.52 (2.39 to 12.66) 0.004 0.59
After 3 months 68.91 (1.86) 48 62.54 (2.07) 41 6.37 (0.87 to 11.87) 0.02 0.49
After 9 months 70.64 (2.09) 47 65.32 (2.25) 45 5.32 (−0.78 to 11.43) 0.09 0.37
Impact subscale
After 1 week 44.95 (1.58) 60 41.43 (1.70) 52 3.52 (−1.03 to 8.07) 0.13 0.29
After 3 months 46.51 (1.83) 51 40.16 (1.93) 49 6.35 (1.10 to 11.61) 0.02 0.48
After 9 months 46.48 (1.96) 50 37.86 (2.03) 49 8.62 (3.04 to 14.21) 0.003 0.62
Symptoms subscale
After 1 week 60.08 (2.53) 64 57.58 (2.67) 57 2.50 (−4.71 to 9.70) 0.50 0.12
After 3 months 59.16 (2.61) 58 53.91 (2.84) 48 5.25 (−2.33 to 12.84) 0.17 0.27
After 9 months 57.48 (2.67) 54 52.37 (2.75) 52 5.11 (−2.43 to 12.65) 0.18 0.26
Total SGRQ scale
After 1 week 55.63 (1.57) 49 50.48 (1.71) 42 5.14 (0.59 to 9.70) 0.03 0.47
After 3 months 56.09 (1.64) 44 49.12 (1.82) 38 6.97 (2.14 to 11.80) 0.005 0.64
After 9 months 56.08 (1.86) 42 48.14 (1.98) 42 7.94 (2.67 to 13.32) 0.004 0.65
Abbreviations: SE, standard error; BDI, Beck Depression Inventory; SCL Anxiety, Symptom Checklist Anxiety; SGRQ, Saint George’s Respiratory
Questionnaire.
Range of the BDI is 0–63, with 0 as the most favorable outcome; range of SGRQ total scale and subscales is 0–100, with 0 as the most favorable
score; range of the SCL Anxiety scale is 1–50, with 1 as the most favorable outcome.
N represents the number of persons with a valid scale score on that FU measurement.
∗Estimates from mixed model regression analyses, corrected for age, gender, level of education and baseline value of the outcome measure.
∗∗The maximum number of patients across measurements for whom imputation of items was not possible was 2 for the BDI, 5 for the SCL, 32 for
Activity, 21 for Impact, 15 for Symptoms and 41 for the SGRQ total score.
COPD-treatment adherence or increased help seeking behavior
may have contributed to the effects found on the SGRQ-scales.
The fact that improvements in quality of life were visible ear-
lier than the improvements in anxiety and depressive symptom
levels, indicates that the intervention seems to have a direct
effect on quality of life. Nevertheless, improvements in anxi-
ety and depression may have mediated further improvements in
quality of life during later follow-up. With respect to treatment
factors that may affect effectivity, additional analyses revealed
no effects of the number if contacts during the intervention or
of which nurse administered the intervention on the outcomes
(data not shown).
As noted by Coventry & Gellatly in their review (17), only
a few studies have evaluated the effectiveness of psychological
treatments for depression and anxiety in COPD patients. The
effect sizes for symptoms of depression and anxiety found in
our study are highly similar to those reported by Coventry and
Gellatly (17). As regards disease-specific quality of life, the
group difference of 7.94 for the SGRQ total score in our study
is higher than the weighted mean difference (WMD) derived
from seven other studies evaluating self-management (WMD
= 2.58;95% CI-0.02 – 5.14) (19), and is also larger than the
accepted cut-off point (four points) for a clinically relevant
change (34). Interestingly, whereas previous analyses found
no effect on generic quality of life (20), we did find an ef-
fect on disease-specific quality of life in the current analyses.
Disease-specific quality of life measures have been shown to be
more responsive to change than generic measures (35). Since
the SGRQ covers specific domains that are important to patients
with COPD, the use of this measure enabled us to detect changes
in quality of life that are of specific importance and relevance
to them but are beyond the scope of generic instruments.
Several potential weaknesses of our study should be consid-
ered. First, dropouts were older and had a lower quality of life
and higher levels of depressive symptoms. Although dropout
was somewhat more common in the intervention group, this
difference was not statistically significant. Despite the use of
mixed models for repeated measures (which include patients
with incomplete observations), this pattern of attrition might
have affected our findings. However, an LOCF analysis, often

























































regarded as a conservative imputation method (36), did not alter
our conclusions. Second, disease severity can be an interfer-
ing factor if severity is unequally divided between groups and
also effectivity of the intervention may differ between moderate
and severe cases of COPD. We did not have objective data on
the severity of COPD among participants at baseline, such as
FEV1 data, since patient inclusion was done by GPs on the basis
of existing practice records. However, disease-specific quality
of life, which has been shown to be related to COPD sever-
ity but may reflect disease impact better (37), did not differ
between groups at baseline. Also, recent research has shown
that a postbronchodilator FEV1/FVC ratio of 0.7 was supported
by SGRQ measurements (38), which may indicate that SGRQ
scores may be used as surrogate markers of lung function. Third,
we included persons who according to their GP had COPD, but
nevertheless some persons may not have had a COPD diagnosis
confirmed by spirometry. Fourth, blinding of patients was obvi-
ously not possible, as we compared the intervention with usual
care, as is often done in pragmatic trials.
Our study had several strengths. Suspected depression, as
picked up by the screening questionnaire, was confirmed by a
DSM-IV based diagnostic interview. Additionally, we included
patients with a wide range of depression severity, so that our
sample reflects the natural heterogeneity of patients with de-
pressive symptoms in primary care. A further strength of our
approach is that nurses were used to administer the interven-
tion. Since nurses are already involved in disease-management
programmes and as such see patients on a regular basis, they
seem obvious candidates for the task of administering psycho-
logical interventions. We have shown that nurses without any
specific psychiatric background can be trained to administer an
MPI that successfully reduces depression and anxiety and im-
proves quality of life. An extensive process evaluation showed
that nurses had adhered closely to the protocol and that they
were highly enthusiastic about the intervention. As for patients,
the evaluation revealed that they were also highly satisfied with
the intervention and would recommend it to other persons with
a chronic illness (27). Chronic disease management strategies
are creating a growing burden on patients, which may lead to
poor adherence, wasted resources and poorer outcomes (39).
The outcomes of the process evaluation however, indicate that
the MPI is very much appreciated by patients and was even rec-
ommended to be offered to all patients with chronic diseases.
MPI therefore seems to be very suitable for incorporation within
disease management programmes, which appears a logical next
step. By taking on the task of depression management within
these programmes, nurses may thus complement the GP’s reg-
ular work. An economic evaluation of the intervention in the
original study population (diabetes and COPD) showed a 63%
probability that the MPI is less costly and more effective than
usual care, and it appeared that the intervention is no more costly
than care as usual (40).
In a time when aging of the population is likely to increase
the prevalence and burden of COPD, maintaining the highest
possible quality of life and slowing down further deterioration
of the COPD patient’s health status will remain the key goals of
COPD treatment. Our nurse-administered minimal psychologi-
cal intervention was effective in reducing anxiety and depressive
symptoms and improving disease-specific quality of life. We
therefore feel that adding MPI to existing disease-management
programmes is likely to improve the care for elderly COPD
patients.
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